Investing Profile

Stacey Seltzer

VC
Partner at Aisling Capital
Photo of Stacey Seltzer, Partner at Aisling Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
The Wharton School Network
429 CONNECTIONS
Mckinsey & Company Network
310 CONNECTIONS
Mckinsey & Company Network
310 CONNECTIONS
Mckinsey & Company Network
310 CONNECTIONS
Mckinsey & Company Network
310 CONNECTIONS
cb
3
$280M
CompanyStageDateRound SizeTotal Raised
Aimmune Therapeutics
Series BMar 2015$80M
$80M
Co-investors: Jim Tananbaum (Foresite Capital Management)
Agile Therapeutics
Post Ipo EquityFeb 2015$20M
Series CJul 2012$40M
$110M
Co-investors: Karen Hong (De Novo Ventures), Andrew Schiff (Aisling Capital)
Business Analyst Mckinsey & CompanyPresent
Director, Business Development AkceliPresent
Director, Business Development Mckinsey & CompanyPresent
Management Associate MerckPresent
Senior Manager, Global Licensing MerckPresent
Associate Director, US Marketing MerckPresent
Principal Aisling CapitalPresent
Board Member Mckinsey & CompanyPresent
Board Member Aimmune TherapeuticsPresent
Board Member Reneo PharmaceuticalsPresent
Partner Aisling CapitalPresent
Partner Gurnet Point CapitalPresent
Managing Partner and Founder Mckinsey & CompanyPresent
Yale University M.S. / B.S. Molecular Biophysics and Biochemistry
Wharton School of Business MBA Healthcare
The Wharton School MBA Healthcare